Filing Overview
Xeris Biopharma Holdings, Inc. filed this Form 8-K on January 28, 2022, under Item 8.01 and Item 9.01. The filing relates to Xeris’s October 5, 2021 acquisition of Strongbridge Biopharma plc and related merger transactions.
Business Context and Reporting Period
- Xeris acquired all outstanding Strongbridge ordinary shares through an Irish-law scheme of arrangement.
- Strongbridge shareholders received 0.7840 Xeris common shares per Strongbridge share, cash in lieu of fractional shares, and one non-tradeable contingent value right potentially worth up to $1.00 per Strongbridge share.
- Xeris Pharma, Inc. merged with a Company subsidiary and survived as a wholly owned subsidiary; outstanding Xeris Pharma equity awards were assumed and converted into equivalent Xeris awards.
- The filing provides Strongbridge’s unaudited consolidated financial statements as of September 30, 2021 and for the nine months ended September 30, 2021.
- It also provides unaudited pro forma condensed combined financial information for Xeris and Strongbridge, giving effect to the Transactions as if completed on January 1, 2020.
Financial Metrics and Pro Forma Information
The filing text provided does not include the numerical financial statements or clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, assets, liabilities, or equity. Those details are contained in Exhibits 99.1 and 99.2.
- Exhibit 99.1: Strongbridge unaudited consolidated financial statements and related notes.
- Exhibit 99.2: Unaudited pro forma condensed balance sheet as of September 30, 2021.
- Exhibit 99.2: Unaudited pro forma condensed combined statements of operations for the year ended December 31, 2020 and the nine months ended September 30, 2021.
Material Changes, Outlook, and Risks
- The principal material event was the completion of the Strongbridge acquisition and related merger on October 5, 2021.
- The contingent value rights may be settled in cash, additional Xeris shares, or a combination, at Xeris’s sole election, subject to the stated maximum value.
- Xeris cautioned that the pro forma information is for informational purposes only and may not represent the financial position or operating results that would have occurred had the Transactions taken place on the stated dates.
- The pro forma information is not intended to predict Xeris’s future combined financial position or results of operations.
- No specific management guidance, operating forecast, new contingency, or quantified risk is provided in the filing text.
Key Facts to Verify
- Review Exhibit 99.1 for Strongbridge’s actual revenue, operating results, cash flows, debt, liquidity, and balance-sheet information.
- Review Exhibit 99.2 for transaction accounting adjustments and the resulting pro forma financial position and operating results.
- Verify the terms, settlement mechanics, and potential dilution or cash exposure associated with the contingent value rights.
- Assess whether the pro forma assumptions and purchase accounting adjustments are reasonable and comparable with subsequent reported results.
- Confirm the effect of the transaction on Xeris’s share count, equity awards, liabilities, and future liquidity.